Steven Mah
Stock Analyst at TD Cowen
(2.23)
# 2,829
Out of 5,044 analysts
29
Total ratings
37.93%
Success rate
11.72%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $32.21 | +80.07% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $27.54 | +12.56% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $12.19 | +884.41% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $5.87 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $21.15 | +98.58% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $5.62 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $1.47 | +580.27% | 1 | Feb 22, 2023 | |
| ABSI Absci | Upgrades: Outperform | n/a | $4.37 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $2.42 | +767.77% | 2 | Jul 15, 2022 | |
| NTRA Natera | Maintains: Overweight | $150 → $155 | $192.81 | -19.61% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $22.73 | +515.93% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $2.01 | +2,487.06% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $95.03 | +336.70% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $27.94 | +794.77% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $32.21
Upside: +80.07%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $27.54
Upside: +12.56%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $12.19
Upside: +884.41%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $5.87
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $21.15
Upside: +98.58%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $5.62
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $1.47
Upside: +580.27%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $4.37
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $2.42
Upside: +767.77%
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $192.81
Upside: -19.61%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $22.73
Upside: +515.93%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $2.01
Upside: +2,487.06%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $95.03
Upside: +336.70%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $27.94
Upside: +794.77%